Further studies on the detection of early lung and breast carcinoma by T antigen

We measured the cellular and humoral autoimmune response to carcinoma (CA)-associated T antigen in patients with the earliest clinical stages of lung (T1N0M0) and breast (Tis) CA. We used desialylated MN glycoprotein from healthy human erythrocytes in a single measurement of 1) delayed-type skin hyp...

Full description

Saved in:
Bibliographic Details
Published inCancer detection and prevention Vol. 8; no. 1-2; p. 95
Main Authors Springer, G F, Fry, W A, Desai, P R, Semerdjian, R A, Tegtmeyer, H, Neybert, C G, Scanlon, E F
Format Journal Article
LanguageEnglish
Published England 1985
Subjects
Antigens, Tumor-Associated, Carbohydrate
Breast Neoplasms - diagnosis
Breast Neoplasms - immunology
Carcinoma - immunology
Disaccharides - analysis
Female
Humans
Hypersensitivity, Delayed
Lung Neoplasms - diagnosis
Lung Neoplasms - immunology
Online AccessGet more information

Cover

More Information
Summary:We measured the cellular and humoral autoimmune response to carcinoma (CA)-associated T antigen in patients with the earliest clinical stages of lung (T1N0M0) and breast (Tis) CA. We used desialylated MN glycoprotein from healthy human erythrocytes in a single measurement of 1) delayed-type skin hypersensitivity response (DTHR-T) and 2) humoral anti-T response with a solid-phase immunoassay (SPIA-T). DTHR-T detected 19/20 lung CA and 10/12 ductal and 7/10 lobular breast CA patients. Sixteen of 18 stage T1N0M0 lung CA patients had a positive SPIA-T as did 7/8 patients with Tis breast CA. Two of 35 patients with benign lung and 11/144 with benign breast disease had a positive DTHR-T. None of 160 persons with either other non-CA diseases or healthy had a positive DTHR-T. Three of 68 such control subjects had a positive SPIA-T. The difference between CA patients and control populations is statistically highly significant.
ISSN:0361-090X